Andrew Chapman

Andrew Chapman has a strong background in chemical and biotechnological research. Andrew is currently the CEO/CSO and co-founder of Carbometrics, where they lead the business, scientific, and operational strategies of the company. Andrew also handles negotiations with universities, collaborators, and other relevant organizations. Additionally, they are a scientific advisor at ARGONAUTE RNA LIMITED, providing expertise in oligonucleotide and bioconjugate chemistry.

In the past, Andrew has served as a non-executive director at Emenda Therapeutics and as a technical due diligence consultant at Revena. Andrew has also been a guest lecturer at the University of Bristol and a senior lecturer in inorganic chemistry at Kingston University. At Kingston University, they established research collaborations and secured both public and private research funding.

Prior to that, Andrew served as a chief scientific officer at Ziylo, a company acquired by Novo Nordisk. In this role, they were responsible for the scientific strategy of the product pipeline and led a research team in multiple disciplines. Andrew played a crucial role in the development of scientific tools, diagnostics, and therapeutics.

Earlier in their career, Andrew worked as a research scientist at Econic Technologies Ltd, where they contributed to the design and build of specialized lab facilities and led research projects in catalyst development. Andrew also worked as a postdoctoral researcher at ICIQ, where they coordinated a research group and conducted research on the synthesis and characterization of precious metal precursors and nanoparticles.

Andrew is currently pursuing a Life Science EMBA at the Biotechnology Business Institute.

Andrew Chapman's education history begins in 2003 when they attended the University of Bristol and obtained a Bachelor of Science in Chemistry (MSci) in 2007. Andrew continued their education at the same institution and pursued a Doctor of Philosophy (PhD) in Chemistry, which they completed in 2012. In 2017, Andrew attended the Cambridge Judge Business School for an Ignite program, although the field of study is not specified. Lastly, in 2022, they enrolled in the Biotechnology Business Institute to earn an Executive MBA in the field of Life Sciences, which they are expected to complete in 2023.